USV has introduced Q-rite tablets, which contain 200 milligrams of Quinidine Sulphate, to help patients suffering from rare irregular heartbeat conditions. This launch marks the first commercial availability of Quinidine Sulphate tablets in India, aimed at enhancing patient care for those with cardiac arrhythmias.
Cardiovascular diseases pose a significant health challenge in India, with around 40% of cardiac patients exhibiting signs of heart rhythm disorders. Alarmingly, 22% of these individuals are at risk of sudden cardiac arrest due to arrhythmia, many of whom are under 40 years old. In response to this urgent need, USV has launched Q-rite tablets to improve patient outcomes in managing arrhythmias.
Mr. Prashant Tewari, Managing Director of USV, emphasized the company’s commitment to addressing patient needs. “We have been empathetic to the needs of patients, especially those with cardiac conditions who lack management options. The launch of Q-rite tablets in India highlights our vision of enhancing accessibility. We believe our focus on niche medications will provide targeted solutions that significantly improve patient outcomes,” he stated.
Experts in the field also recognize the importance of Quinidine’s availability in India. Dr. Aditya Kapoor, President of the Indian Society of Electrocardiology (ISE), and Dr. Ketan Mehta, Honorary General Secretary of ISE, noted in a joint statement, “Quinidine, being an old yet versatile antiarrhythmic drug, will adequately address the needs of a select group of patients.”
Q-rite tablets are now available at select pharmacies in hospitals and can also be purchased through the online pharmaceutical retailer Tata 1mg. This development is expected to provide critical support for patients managing arrhythmias and enhance overall cardiac care in India.
Related topics:
- Exploring Alternative Treatments for Atrial Fibrillation: September Is Atrial Fibrillation Awareness Month
- Researchers Identify New Target for Heart Failure Treatment: Protein Kinase N
- CVRx Reports Positive Two-Year Data for Heart Failure Treatment Device